Characteristics of studies used to support FDA lung cancer approvals (2006 to 2018) made via the accelerated vs regular pathways and BTD vs non-BTD.

Characteristics of studies used to support FDA lung cancer approvals (2006 to 2018) made via the accelerated vs regular pathways and BTD vs non-BTD.

用于支持2006至2018年美国食品药品监督管理局（Food and Drug Administration, FDA）肺癌药物获批的相关研究的特征，此类获批分别采用加速审批途径与常规审批途径，且涵盖突破性疗法认定（Breakthrough Therapy Designation, BTD）与非BTD两种情形。